This article is neither a theoretical treatise on psychopharmacotherapy nor an attempt to summarize psychopharmacological research in Europe. It describes Yugoslav practice and experience in treating people who suffer from the various forms of schizophrenia, and is thus not a comprehensive description of the practices of European psychiatrists. To aim at such a description would be a vain effort. There are at least twice as many schools of psychiatry as there are countries in Europe; and few of the practicing psychiatrists remain within their school's rules during their working life.
Even Yugoslav practice and teaching has changed considerably over the years. It will undoubtedly continue changing with new discoveries, and more experience. In spite of these limitations, I believe that what is described here would be accepted as the usual practice of treatment of schizophrenia in Europe. This belief is based on contacts with VOL. 12, NO. 1, 1986 21 colleagues and observations of psychiatrists in different countries of Europe. It is not based on a study of published work for the simple reason that there is no consensus description of the most commendable treatment of schizophrenia or, for that matter, much more than textbook instructions which are usually given in fairly general terms. There is little doubt that much of the healing art and practice in Europe is still transmitted in apprenticeship instead of through written instruction.
Psychopharmacological treatment has assumed the central place in the treatment of schizophrenia in all of the European countries (Shepherd, Lader, and Rodnight 1968) . Psychotherapy and social measures are recognized as important and used in conjunction with medication. There are clear variations in the social and psychotherapeutic methods employed, as well as in the degree of importance attached to them.
Medications used in the psychopharmacotherapy of schizophrenia are usually divided into two major groups (Angst 1969; Benkert and Hippius 1974; Heinrich 1976) : The first are basic (or nonspecific) neuroleptics. They are given in high doses, and have a global influence on the majority of symptoms seen in schizophrenia, including agitation, insomnia, restlessness, hallucinations, and delusions. They tend to have fewer extrapyramidal side effects and a stronger sedative action than drugs in the second group. The second group comprises drugs that are given in relatively small doses and appear to be more specific in their action.
The following characteristics of schizophrenia are generally considered in decisions about pharmacotherapy:
• Clinical form of schizophrenia (simple, hebephrenic, catatonic, or paranoid).
• Course of disease and phase in which treatment is prescribed (acute or chronic).
• Dominant symptoms (agitation, stupor, apathy, or abulia).
• Balance between productive (positive) and nonproductive (negative) symptoms.
Psychopharmacotherapy in Relation to Illness Characteristics
Clinical Form.
1 In simple and hebephrenic schizophrenia, basic neuroleptics are used first, and specific neuroleptics may not be used at all. If the latter are used, they will be administered after treatment with basic neuroleptics has been tried for some time. In catatonic excitement, both basic and specific drugs are used, whereas in catatonic stupor, specific drugs are prescribed. In paranoid, hallucinatory forms of schizophrenia, treatment begins immediately with specific drugs; later, and only occasionally, some of the nonspecific symptoms (such as insomnia) will be treated by basic drugs.
The principle of using as few drugs as possible is observed in most settings. In addition to neuroleptic treatment, a patient is usually also given antiparkinsonian drugs and ' In describing clinical syndromes and assessing change of the patient's condition in the course of treatment, a variety of instruments have been used. The Present State Examination (World Health Organization 1973 and the AMP System (Association for Methodology and Documentation in Psychiatry) (Angst et al. 1969; Bobon 1978; Bohacek 1978) are examples of some of the instruments used in a number of countries.
sometimes antidepressants. As a rule, these combinations are used with less reluctance than the combination of several neuroleptics, although there are some clinics in which a large number of neuroleptics are used at the same time.
Course of Illness. The acuteness of the disease plays a major role in decisions concerning drug type and dosage. In very acute cases, basic neuroleptics such as chlorpromazine, levomepromazine, and promazine (reported to be well tolerated in the elderly) are prescribed. Shortly thereafter, specific neuroleptics (such as fluphenazine, trifluoperazine, thioproperazine, clozapine, and haloperidol) are added depending on the clinical syndrome that dominates the picture. In acute cases, the doses are usually high-as much as 1,200 mg of chlorpromazine, 600 mg of levomepromazine, or 600 mg (or even more) of promazine. Fluphenazine, trifluoperazine, and thioproperazine are given in doses > 30-60 mg/day. In chronic forms of schizophrenia (and for the maintenance of remission), thioridazine and pimozide, as well as depot preparations (see below), are used. Doses of thioridazine range from 200-600 mg/day; doses of pimotide, 4-12 mg/day. Dominant Symptoms. A patient with a dominant picture of psychomotor excitement is given basic neuroleptics, whereas in a patient with psychomotor stupor or retardation, specific neuroleptics are preferred. In a patient with paranoid or paranoid/ hallucinatory symptomatology, specific neuroleptics are used from the beginning. In the instance of apathic or apathic/abulic syndromes, most of the basic neuroleptics have little effect. Specific neuroleptics do seem to have some effect in such cases and are therefore preferred-for example, pipothiazine, thiopro-. perazine, and trifluoperazine. Clozapine has also been reported to have a good effect in the treatment of this syndrome.
Presence of Productive Symptoms. The balance of productive (positive) and nonproductive (negative) symptoms of schizophrenia is also a factor in decisions concerning the type and dosage of neuroleptics to be prescribed. Most neuroleptics are efficacious in treating positive symptoms (such as hallucinations or excitement), but their effects in treating negative symptoms (such as apathia-abulia) are far less dramatic. There have been attempts to use psychostimulants (amphetamines or sidnocarb) (Persic et al. 1972 ) and even hallucinogens (LSD-25 or Deanol) (Fouks et al. 1966 ) to deal with negative symptoms. It is hoped that such agents will precipitate positive symptoms, which will be more amenable to standard treatment with neuroleptics.
Drug Combinations
Occasionally a single medication can be sufficient to achieve a full therapeutic effect. In most instances, however, psychiatrists prescribe several medications simultaneously. For example, neuroleptics are used to treat the' main symptoms, hypnotics to treat subsidiary symptoms, antiparkinsonian drugs to correct side effects, and so on.
Even in dealing with the main symptoms of schizophrenia, the use of only one neuroleptic is more the exception than the rule. Basic neuroleptics such as levomepromazine are often combined with a specific "target" neuroleptic such as fluphenazine even though it is widely recognized that such combinations can potentiate side effects (e.g., extrapyramidal or hypotensive effects or transient delirious states). Occasionally a combination of neuroleptics with drugs such as diazepam is prescribed. The latter is usually given in high doses. Accessory symptoms (such as insomnia) sometimes warrant additional therapy with hypnotic drugs or levomepromazine. Benzodiazepines (e.g., nitrazepam and flurazepam) are also added in these cases (although this type of combination has been shown to cause tiredness and slowness) because of possible interactions of barbiturates with neuroleptics (e.g., the induction of microsomal liver enzymes, which in turn can lead to a decrease of the effectiveness or elimination of effects of psychopharmacological drugs). Combined treatment with several neuroleptics is also sometimes used to avoid side effects.
Management of Side Effects
Early extrapyramidal side effects (e.g., tremor, rigidity, akathisia, and dyskinesia) are treated with antiparkinsonian drugs such as biperidine, trihexyphenidyl, and ethybenztropine. Their administration is often stopped after a short time without a reappearance of extrapyramidal side effects, which may have been intense earlier in treatment.
In general, however, it is no longer considered necessary to continue giving antiparkinsonian drugs indefinitely, and they are not universally used to prevent extrapyramidal side effects. The earlier practice of providing antiparkinsonian drugs to all patients treated with neuroleptics was abandoned when it became clear that no more than half the patients treated with neuroleptics would experience extrapyramidal side effects, and when it was reported that antiparkinsonian drugs increased the risk of tardive dyskinesia (Gerlach 1979) . There is also a possibility that combined treatment with neuroleptics and antiparkinsonian drugs decreases the concentration of neuroleptics in plasma and thus decreases their antipsychotic activity. Moreover, anticholinergic drugs (thus, also antiparkinsonian drugs), when combined with a phenothiazine, can lead to a disturbance of thermoregulatory centers and result in hyperpyrexia. More recently, reports of the serious nature of anticholinergic effects of antiparkinsonian drugs (e.g., dryness of mouth, disturbances of visual accommodation, and micturition) and the fact that the use of some anticholinergic drugs (such as trihexyphenidyl) can lead to dependence further discouraged the routine use of antiparkinsonian drugs as preventive medicine (Vinar 1973; Cattabeni et al. 1980 ).
The most serious and treatmentrefractory example of late extrapyramidal side effects-tardive dyskinesia-has been reported in all European countries. In hospitalized patients, the reported incidence of tardive dyskinesia varies between 0.5 and 40 percent of all patients treated; most reports give a figure of about 15 percent. In chronic patients, the reported range (5 to 20 percent) is smaller. The reasons for these differences in the reported incidence of tardive dyskinesia are unclear and insufficiently investigated. Most reports state that dyskinesia will occur after long-term treatment with neuroleptic drugs (usually after 2 to 5 years), but cases occurring after 6 months of therapy have been described.
A variety of treatments have been tried but without much success. Since there is no effective therapy for tardive dyskinesia, attempts are being made to prevent its occurrence by following these principles:
(1) Every attempt should be made to achieve and maintain optimal effects with the smallest possible dose.
(2) Very high doses should be avoided at all times. (3) Wherever possible, treatment with antiparkinsonian (anticholinergic) drugs should be avoided; if these drugs are considered necessary, their use should be interrupted at regular intervals. (4) "Drug holidays" should be employed when the patient's condition permits. (5) An intensive effort should be made to train practitioners to recognize tardive dyskinesia in its incipient stages.
Various psychological side effects of neuroleptic treatment have been described and linked to the dose of neuroleptics, combination of drugs used, and the premorbid personality structure and age of the patient. One such effect which requires immediate cessation of all treatment is the transient delirious state that is most often seen when neuroleptics are used together with antidepressant and/or antiparkinsonian drugs. Another side effect described in protracted treatment with neuroleptics is the "depressive shift": the occurrence of a depressive syndrome in the course of treatment with neuroleptic drugs, usually after the acute symptoms (especially in paranoid/hallucinatory forms of schizophrenia) have disappeared (Bohacek 1965; Muller 1981) . Such a depressive shift (or postpsychotic depression) has been found in patients treated with all types of neuroleptics, from phenothiazines to butyrophenones. It can be seen in 15-20 percent of all those treated. If left unattended, this depressive syndrome can lead to suicide and attempted suicide. The condition responds well to tricyclic and tetracyclic antidepressants (e.g., imipramine, amitriptyline, and maprotiline), which can be given in combination with neuroleptic drugs. Some authors have argued that the syndrome of postpsychotic depression does not exist. If a depressive syndrome occurs in the course of treating schizophrenia, these authors believe that a mixed state in which schizophrenic and depressive syndromes were present must have existed before treatment began. Others believe that the depressive shift is, in fact, a syndrome of exhaustion that occurs after remission from schizophrenia (der "post remissive Erschoepfungszustand"; Heinrich 1967) .
When physical disease occurs in patients with schizophrenia, it is generally agreed that it is essential to provide additional therapy for the concurrent diseases while maintaining neuroleptic treatment. Such combined therapy can lead, however, to untoward interaction between drugs and side effects. Among these, the following are the most frequently reported: (1) The combination of oral antidiabetic drugs (of sulfonyleurea type) with neuroleptics of the phenothiazine type can decrease the effectiveness of phenothiazines. 
Duration of Neuroleptic Therapy
Neuroleptics are generally seen as a symptomatic treatment. To be effective, neuroleptic treatment must coincide with the presence of manifest symptoms of the disease: in this sense, by pharmacological parallel, neuroleptic treatment could be called "psychostatic."
Up to 80 percent of schizophrenic psychoses in our experience follow a chronic course. In these patients permanent pharmacotherapy is necessary. Because it is impossible to predict with certainty whether recovery from an acute episode of schizophrenia will be followed by relapses, and whether schizophrenia will follow a chronic course, in our practice pharmacotherapy is continued for approximately 1 year after the first attack. At that point, if the patient's condition permits, neuroleptic treatment is stopped. If symptoms of the initial episode are still present, treatment is continued. If a patient has a relapse (i.e., a second episode of the disease), treatment is continued for 3 years from the time of the second episode. If a third attack occurs, it is generally considered that pharmacotherapy will have to be lifelong. These guidelines provide a general framework within which adjustments for the individual patient are necessary (Palmovic and Bohacek 1970) .
Maintenance Therapy
After recovery from the acute phase of schizophrenia has occurred, drug dosages are gradually decreased to a minimum necessary to maintain an asymptomatic state. This decreased dose will be Vt, Y 5 , or even y 10 of the dose that was necessary during the acute phase.
Prolonged pharmacotherapy once required patients to take the neuroleptic in three or four daily doses-a difficult regimen to follow. Today, 24 SCHIZOPHRENIA BULLETIN however, a variety of depot neuroleptics is used: in the group of tricyclic phenothiazirtes, fluphenazine enanthate and decanoate, perphenazine enanthate, flupenthixol decanoate, pipotiazine undecilatester, and pipotiazine palmitinester (which can maintain the blood levels constant from 7 to 28 days); among butyrophenones, haloperidol decanoate (supposed to maintain the therapeutic action of haloperidol for a period of approximately 4 weeks); among diphenylbutyrylpiperidenes, pimozide (taken once every day or every 2 days), fluspiriline (once weekly), and penfluridol (once weekly when taken orally) (Doongaji et al. 1981) .
There is general agreement about the advantages of treatment with depot preparations: they are easy to apply, there is a good local and general tolerance, and the patient feels less marked as a mentally disordered person when he can receive treatment in a general health facility. There are also numerous reports that this form of treatment leads to a better relationship and transference between the patient and the doctor, greater possibilities for the use of other treatment methods (such as psychotherapy and sociotherapy), fewer side effects (in particular, extrapyramidal side effects), and a reduced danger of suicide, which was a particular risk in countries where the scarcity of services made it necessary to prescribe medication in sufficient quantities to last a month and to give it to the patient in a health facility.
Social Implications of Psychopharmacological Treatment
Psychopharmacotherapy is undoubtedly an effective treatment for schizophrenia. It by far surpasses the effectiveness of previous biological treatments and poses considerably fewer risks. The improved treatment of schizophrenia has had numerous social consequences, ranging from changes in attitudes to changes in legislation and organization of health services. Reports from various parts of Europe suggest that the attitudes of the patient, his family, lay personnel, and professionals toward the disease and its treatment are significantly more positive. Confidence in the efficacy of pharmacotherapy is constantly increasing.
The main social implication of the introduction of pharmacotherapy has been the possibility of outpatient treatment of a large number of schizophrenic patients who previously would have been institutionalized.
Although empirical observations were very important in establishing the efficacy of psychopharmacotherapy-the clinician's eye was the instrument that discovered the antipsychotic and antidepressive action of pharmacological drugspsychopharmacological treatment led to the development of objective measurement techniques in psychiatry. These methodological advances have contributed to the scientific evidence about the value of different pharmacological drugs, so that results no longer rest only on clinical impressions. They have also made a contribution to the technology of assessment of complex human behavior. The pharmacotherapy of schizophrenic psychoses has also made it feasible to apply social and psychological therapeutic measures and to provide help for the schizophrenic and his family (Bohacek 1973) .
There is much more agreement among psychiatric schools (regardless of their social, economic, political, and other differences) about principles of pharmacotherapy than there is similarity in the provision of treatment in different European countries. This is so for a variety of reasons. Pharmacotherapy, for example, is dependent on the social system, the philosophy of health care, and the organization of health services in general. In some European countries, health care is free and comprehensive; in others, health care is only free in part; and in others, much depends on the capacity of the patient and his family to pay the often exorbitant fees.
Conclusion
Much hope, and even more money and other resources are being invested in the search for new neuroleptics that will (1) be more effective and therefore applicable in smaller doses; (2) have an even more prolonged effect; (3) be more effective in dealing with nonproductive symptoms; and (4) have few or no side effects.
A question that psychopharmacology must resolve in the process of searching for new drugs is that of specificity of psychopharmacological substances. True specificity would mean that drugs used for the treatment of depression and schizophrenia were, in fact, specific for these diseases-which cannot today be affirmed for any one of the substances used.
In addition to these improvements in the psychopharmacological arsenal, most European countries are trying to improve the organization of services and other components of care. In this process the potential of different modes of treatment-with psychopharmacological, social, and biological means-has to be reexamined, and ways to ensure the provision of treatment that will satisfy the patient, his family, and the community must be found.
